Trial Profile

A phase 2a single arm study to evaluate the effect of TCN -202 (human anti-cytomegalovirus monoclonal antibody) on CMV infection in CMV (cytomegalovirus) seronegative recipients of kidney allografts from CMV seropositive donors

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 27 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Dec 2013 Initiation date changed from 10 September 2013 to 27 August 2013, as per Brazilian Clinical Trials Registry record
11 Dec 2013 As per Brazilian Clinical Trials Registry record, the expected date of last enrollment is 31 May 2014
11 Dec 2013 As per the Brazilian Clinical Trials Registry record; the primary endpoint has been changed form viral load to proportion of patients receiving the CMV infection. The dose has been changed from 1 mg/ kg to 15 mg/kg.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com